Arritmias en el embarazo Translated title: Arrhythmia during pregnancy

Young age and inducibility of atrioventricular reciprocating tachycardia or atrial fibrillation during invasive electrophysiological testing identify asymptomatic patients with a Wolff-Parkinson-White pattern on the electrocardiogram as being at high risk for arrhythmic events. We tested the hypothesis that prophylactic catheter ablation of accessory pathways would provide meaningful and durable benefits as compared with no treatment in such patients. From 1997 to 2002, among 224 eligible asymptomatic patients with the Wolff-Parkinson-White syndrome, patients at high risk for arrhythmias were randomly assigned to radio-frequency catheter ablation of accessory pathways (37 patients) or no treatment (35 patients). The end point was the occurrence of arrhythmic events over a five-year follow-up period. Patients assigned to ablation had base-line characteristics that were similar to those of the controls. Two patients in the ablation group (5 percent) and 21 in the control group (60 percent) had arrhythmic events. One control patient had ventricular fibrillation as the presenting arrhythmia. The five-year Kaplan-Meier estimates of the incidence of arrhythmic events were 7 percent among patients who underwent ablation and 77 percent among the controls (P<0.001 by the log-rank test); the risk reduction with ablation was 92 percent (relative risk, 0.08; 95 percent confidence interval, 0.02 to 0.33; P<0.001). Prophylactic accessory-pathway ablation markedly reduces the frequency of arrhythmic events in asymptomatic patients with the Wolff-Parkinson-White syndrome who are at high risk for such events. Copyright 2003 Massachusetts Medical Society

The treatment of arrhythmias during pregnancy is complicated by concerns for fetal well-being. Although no drug is absolutely safe, most are well tolerated. Nonpharmacologic therapy includes vagal maneuvers and esophageal pacing. Temporary and permanent pacing have been used safely during pregnancy, as has direct current cardioversion. Cardiopulmonary resuscitation is complicated by concerns for the fetus, which may be viable at 25 weeks. Diagnosis of the cause of tachyarrhythmias may be enhanced by roving chest leads or esophageal recording. Both supraventricular and ventricular tachycardias may become manifest during pregnancy, and conservative management is desirable if the symptoms are mild. Supraventricular tachycardias respond acutely to adenosine. Ventricular arrhythmias during pregnancy often occur in the absence of structural heart disease and are responsive to drug therapy. The safe use of an implantable cardioverter-defibrillator has been described.